Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model

被引:54
作者
McConville, Jason T.
Overhoff, Kirk A.
Sinswat, Prapasri
Vaughn, Jason M.
Frei, Bradi L.
Burgess, David S.
Talbert, Robert L.
Peters, Jay I.
Johnston, Keith P.
Williams, Robert O., III
机构
[1] Univ Texas, Coll Pharm, Austin, TX 78712 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA
[3] Univ Texas, Hlth Sci Ctr, Dept Med, Div Pulm Dis Crit Care Med, San Antonio, TX 78229 USA
[4] Univ Texas, Dept Chem Engn, Austin, TX 78712 USA
关键词
antifungal; fungal infection; nanoparticle; nebulization; poorly water-soluble;
D O I
10.1007/s11095-006-9904-6
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The purpose of this study was to investigate the delivery of itraconazole (ITZ) particles to a murine lung model by nebulization. Three ITZ formulations were prepared and characterized in the dry state using contact angle, dissolution, X-ray powder diffraction, scanning electron microscopy, and Brunauer-Emmett-Teller surface area analysis. Aerodynamic particle size distributions and lung deposition studies in 14 outbred male ICR mice were performed using aqueous dispersions of all the formulations. A separate dosing uniformity study was also performed to qualify use of the chamber. All formulations had an aggregated particle size of approximately 30 mu m in diameter. Two formulations showed that 80% of the drug dissolved in less than 5 min. The remaining ITZ formulation had a slower dissolution and the lowest total emitted dose from the nebulizer used. High concentrations of ITZ were shown to be present in the mouse lung during the lung deposition study, up to 16.8 +/- 0.13 mu g/g (+/- SE) were achieved. Concentrations of up to 0.76 +/- 0.03 mu g/g (+/- SE) could be maintained from the single nebulized dose for at least 24 h. An effective method of targeted delivery of ITZ to the deep lung is presented that may be useful for the treatment and prevention of acute fungal infections.
引用
收藏
页码:901 / 911
页数:11
相关论文
共 31 条
[1]   EVALUATION OF SCH51048 IN AN EXPERIMENTAL-MODEL OF PULMONARY ASPERGILLOSIS [J].
ALLENDOERFER, R ;
LOEBENBERG, D ;
RINALDI, MG ;
GRAYBILL, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1345-1348
[2]   A DEM simulation and experimental strategy for solving fine powder flow problems [J].
Baxter, J ;
Abou-Chakra, H ;
Tüzün, U ;
Lamptey, BM .
CHEMICAL ENGINEERING RESEARCH & DESIGN, 2000, 78 (A7) :1019-1025
[3]   COMPARISON OF THE MULTIPLE DOSE PHARMACOKINETICS OF 2 FORMULATIONS OF ITRACONAZOLE DURING REMISSION INDUCTION FOR ACUTE MYELOBLASTIC-LEUKEMIA [J].
BRADFORD, CR ;
PRENTICE, AG ;
WARNOCK, DW ;
COPPLESTONE, JA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (04) :555-560
[4]   Practice guidelines for the management of patients with blastomycosis [J].
Chapman, SW ;
Bradsher, RW ;
Campbell, GD ;
Pappas, PG ;
Kauffman, CA .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :679-683
[5]   Rapid dissolution of high potency itraconazole particles produced by evaporative precipitation into aqueous solution [J].
Chen, X ;
Benhayoune, Z ;
Williams, RO ;
Johnston, KP .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2004, 14 (04) :299-304
[6]   Invasive aspergillosis [J].
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (04) :781-803
[7]   Practice guidelines for the treatment of coccidioidomycosis [J].
Galgiani, JN ;
Ampel, NM ;
Catanzaro, A ;
Johnson, RH ;
Stevens, DA ;
Williams, PL .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (04) :658-661
[8]  
GRIFFIN DH, 1994, FUNGAL PHYSL, P375
[9]   Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum [J].
Gubbins, PO ;
Gurley, BJ ;
Bowman, J .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 16 (06) :1005-1012
[10]   Stable amorphous danazol nanostructured powders with rapid dissolution rates produced by spray freezing into liquid [J].
Hu, JH ;
Johnston, KP ;
Williams, RO .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2004, 30 (07) :695-704